Rikshospitalet has chosen VeriQ C

(Oslo, July 4th 2013) Medistim announces that Rikshospitalet has chosen to strengthen its quality assurance program of coronary bypass surgery by investing in Medistims top model, VeriQ C. (more…)

Read more

Q1 2013 financial report

Medistim reports sales revenues of MNOK 45,5 (45,1) and operating result of MNOK 7,3 (7,6) in the first quarter of 2013. The positive development in the USA continues, with 14% growth in revenues. The General…

Read more

Medistim Moves into new and modern facilities

(Oslo, March 18th, 2013) Medistim ASA announces that its corporate headquarter today is moving into new and modern facilities in Oslo. At the same time, Medistims sales and distribution center in Norway, Medistim Norge AS,…

Read more

Record Sales in Q4 2012

Medistim delivers record sales in Q4 2012 with MNOK 49.7 (MNOK 41.3). Strong growth of 13.6% for the full year, reaching MNOK 183.8 (MNOK 161.8). Operating profit (EBIT) for the quarter was MNOK 6.1 (MNOK…

Read more

Significant endorsement boosts Medistim Inc.’s life-saving technology

Findings substantiate the VeriQ system’s ability to improve outcomes for coronary artery bypass surgery and contain costs.

MINNEAPOLIS, MINN. (Nov. 17, 2011) – A longtime leader in setting world-class standards for health care is recognizing the effectiveness of a life-saving technology produced by an international medtech company that has a vibrant presence in the United States.

Read more

Medistim’s First Sale of VeriQC™ in the US

Medistim has signed contracts with three hospitals in the US and achieved its first revenues from the company’s new product VeriQC.

All three hospitals have entered into a lease agreement where they pay per usage. A procedure with VeriQC is priced at about twice the level of a procedure performed using the traditional equipment VeriQ™. The company expects that existing and new customers gradually will convert to VeriQC. 

Read more